January 04, 2019
Rose
In the first major pharmaceutical deal of 2019, Bristol-Myers Squibb says it will buy Celgene, a maker of cancer-fighting drugs, in a merger valued at $74 billion. According to Stat, Bristol-Myers has been under pressure to set a new course since August 2016, when a big study of its cancer immunotherapy, Opdivo, failed to show a benefit in previously untreated patients with non-small cell lung cancer. Analysts look at what the deal means to the industry at large.
from Kaiser Health News http://bit.ly/2VxhSnI
January 04, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Politically, There’s Little Public Pressure To Enforce Mental Health Parity Laws, Patrick Kennedy Says- Tight-Knit Communities Pose Unique Challenge To Public Health Officials During Outbreaks
- Many Patients Facing Surprise Medical Bills Just Give In And Pay Rather Than Undertake Behemoth Battle Against Charges
- ‘Heartbeat’ Legislation Designed To Invite Challenge: ‘We Want This Bill To Go To The Supreme Court. It Was Written For This Purpose.’
- Sheer Scale Of Opioid Epidemic Challenges Southern States’ Resistance To Harm Reduction Strategies
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment